Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 97 of 119 for:    ZIRCONIUM

Non-invasive Solution for Periodontal and Peri-implant Diseases (INPERIO) (INPERIO)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03977714
Recruitment Status : Recruiting
First Posted : June 6, 2019
Last Update Posted : June 6, 2019
Sponsor:
Collaborators:
Horizon 2020 - European Commission
ICOA Noroeste SLP
National Research Council, Spain
Experior
Information provided by (Responsible Party):
Nanoker Research S.L.

Brief Summary:

DESCRIPTION: The Investigational Product "A-Ce toughened TZP nanocomposite implant" is a Medical Device (MD) intended for the dental rehabilitation of edentulous sites with fixed prosthesis. The "G3®-coated NK2® abutment" is a MD intended for the prevention of peri-implant bone loss due to peri-implantitis. The MD are for dental use and will be used exclusively on subjects who have signed an informed consent form and by approved study investigators.

OBJECTIVES: (a) To evaluate the safety and performance of the "A-Ce toughened TZP nanocomposite Implant" for its intended medical application purpose in the context of successful osseointegration of zirconia-based dental implants. (b) To evaluate the safety and performance of the "G3®-coated NK2® abutment" for its intended purpose in the context of peri-implantitis prevention. (c) To obtain the regulatory CE Mark Certification status for both medical devices.

TYPE OF INVESTIGATION: Randomized double-blind (patient, appraiser) controlled study.

CENTER/COUNTRY: Instituto de Cirugía Oral Avanzada (ICOA), Madrid, Spain

GROUPS:

Group A: 30 zirconia implants with 30 G3-coated abutments (test implant and abutment) Group B: 30 test implants with 30 uncoated (control) abutments Group C: 30 Ti implants (control) with 30 test abutments Group D: 30 control implants with 30 control abutments Group E: 3 test implants and 3 control implants, for histological/histomorphometric evaluation.

COMPARATIVE DEVICE: Commercial Ti dental implant.

STATISTICAL METHODOLOGY:

H0 : INPERIO performs worse (with statistical significance) than the commercial devices.

  • Test implants achieve a higher failure rate than Ti implants.
  • The clinical osseointegration parameter values are worse with statistical significance for test implants than for control implants.
  • Histological and histomorphometric analysis shows worse quality and quantity of osseointegration for test implants than for Ti implants.

H1: There is no statistical significance between INPERIO and the commercial solution or INPERIO performs better (with statistical significance) than the commercial Ti implants.

  • Test implants achieve the same failure rate or less than Ti implants.
  • The clinical osseointegration parameter values are no different or are better with statistical significance for test implants than for control implants.
  • The histological and histomorphometric analysis shows a similar or better quality and quantity of osseointegration for test implants than for Ti implants.

Condition or disease Intervention/treatment Phase
Peri-Implantitis Device: Zirconia implants with G3-coated abutments (test implants and abutments) Device: Zirconia implants with control abutments (test implants, negative control abutments) Device: Titanium implants with G3-coated abutments (control implants, test abutments) Device: Titanium implants with control abutments (negative control implants and abutments) Device: Zirconia implants and titanium implants, for histological and histomorphometric evaluation. Not Applicable

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 60 participants
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Double (Participant, Outcomes Assessor)
Primary Purpose: Prevention
Official Title: Non-invasive Solution for Periodontal and Peri-implant Diseases
Actual Study Start Date : May 17, 2019
Estimated Primary Completion Date : December 31, 2020
Estimated Study Completion Date : December 31, 2020

Arm Intervention/treatment
Experimental: Group A - test implant and abutment
Zirconia implant and G3-coated abutment (test implant and abutment). Dental sites that potentially qualify for dental implant rehabilitation will be randomly assigned to either the test group (zirconia implants) or the control group (titanium implants). Also, G3-coated and control (non-coated) abutments will be equally distributed on test and control implants, to discriminate between peri-implantitis prevention due to the G3-coating or due to the specific implant characteristics. This is a split-mouth study so that each participant can act as his or her own control and to allow between and within group comparisons.
Device: Zirconia implants with G3-coated abutments (test implants and abutments)
Test and control interventions correspond to those usually applied in dental implantology. The "two-step protocol" will be followed. Local anesthesia will be applied. A flap will be raised to perform a progressive perforation with a gradual increase of the orifice and a profuse irrigation until the bone preparation adapts perfectly to the implant. Implants will wear a closure cap and will be covered within the gingival flap during osseointegration (eight weeks), after which they will be exposed to evaluate secondary stability and to place the abutment, for which local crestal anesthesia will be applied. To expose the closure cap, a tissue punch will generally be used. Once placed, the abutments will not be removed from the implants. All abutments will be covered with a PEEK healing cap during prosthesis fabrication. Finally, the implants will be rehabilitated with fixed prostheses according to the needs of each patient. A follow-up period of 1 year is expected.

Experimental: Group B - test implant and control abutment

Zirconia implant and control abutment (test implant, negative control abutment).

Dental sites that potentially qualify for dental implant rehabilitation will be randomly assigned to either the test group (zirconia implants) or the control group (titanium implants). Also, G3-coated and control (non-coated) abutments will be equally distributed on test and control implants, to discriminate between peri-implantitis prevention due to the G3-coating or due to the specific implant characteristics. This is a split-mouth study so that each participant can act as his or her own control and to allow between and within group comparisons.

Device: Zirconia implants with control abutments (test implants, negative control abutments)
Test and control interventions correspond to those usually applied in dental implantology. The "two-step protocol" will be followed. Local anesthesia will be applied. A flap will be raised to perform a progressive perforation with a gradual increase of the orifice and a profuse irrigation until the bone preparation adapts perfectly to the implant. Implants will wear a closure cap and will be covered within the gingival flap during osseointegration (eight weeks), after which they will be exposed to evaluate secondary stability and to place the abutment, for which local crestal anesthesia will be applied. To expose the closure cap, a tissue punch will generally be used. Once placed, the abutments will not be removed from the implants. All abutments will be covered with a PEEK healing cap during prosthesis fabrication. Finally, the implants will be rehabilitated with fixed prostheses according to the needs of each patient. A follow-up period of 1 year is expected.

Experimental: Group C - control implant and test abutment
Titanium implant and G3-coated abutment (control implant, test abutment). Dental sites that potentially qualify for dental implant rehabilitation will be randomly assigned to either the test group (zirconia implants) or the control group (titanium implants). Also, G3-coated and control (non-coated) abutments will be equally distributed on test and control implants, to discriminate between peri-implantitis prevention due to the G3-coating or due to the specific implant characteristics. This is a split-mouth study so that each participant can act as his or her own control and to allow between and within group comparisons.
Device: Titanium implants with G3-coated abutments (control implants, test abutments)
Test and control interventions correspond to those usually applied in dental implantology. The "two-step protocol" will be followed. Local anesthesia will be applied. A flap will be raised to perform a progressive perforation with a gradual increase of the orifice and a profuse irrigation until the bone preparation adapts perfectly to the implant. Implants will wear a closure cap and will be covered within the gingival flap during osseointegration (eight weeks), after which they will be exposed to evaluate secondary stability and to place the abutment, for which local crestal anesthesia will be applied. To expose the closure cap, a tissue punch will generally be used. Once placed, the abutments will not be removed from the implants. All abutments will be covered with a PEEK healing cap during prosthesis fabrication. Finally, the implants will be rehabilitated with fixed prostheses according to the needs of each patient. A follow-up period of 1 year is expected.

Active Comparator: Group D - control implant and abutment
Titanium implant and control abutment (negative control implant and abutment). Dental sites that potentially qualify for dental implant rehabilitation will be randomly assigned to either the test group (zirconia implants) or the control group (titanium implants). Also, G3-coated and control (non-coated) abutments will be equally distributed on test and control implants, to discriminate between peri-implantitis prevention due to the G3-coating or due to the specific implant characteristics. This is a split-mouth study so that each participant can act as his or her own control and to allow between and within group comparisons.
Device: Titanium implants with control abutments (negative control implants and abutments)
Test and control interventions correspond to those usually applied in dental implantology. The "two-step protocol" will be followed. Local anesthesia will be applied. A flap will be raised to perform a progressive perforation with a gradual increase of the orifice and a profuse irrigation until the bone preparation adapts perfectly to the implant. Implants will wear a closure cap and will be covered within the gingival flap during osseointegration (eight weeks), after which they will be exposed to evaluate secondary stability and to place the abutment, for which local crestal anesthesia will be applied. To expose the closure cap, a tissue punch will generally be used. Once placed, the abutments will not be removed from the implants. All abutments will be covered with a PEEK healing cap during prosthesis fabrication. Finally, the implants will be rehabilitated with fixed prostheses according to the needs of each patient. A follow-up period of 1 year is expected.

Experimental: Group E - test and control implants

Zirconia implant and titanium implant for histological and histomorphometric evaluation.

This study will be performed in the area of the wisdom teeth (a "non useful" site that will not interfere with the rest of the study or with the patient's life), so it can only be performed in patients who no longer have these teeth. The procedure will match the procedures described for Groups A-B-C-D. Group E implants will only remain in the mouth for 2 months, after which they will be removed for further analysis. The removal of these implants, for the patient, has exactly the same implications as a normal molar extraction.

Device: Zirconia implants and titanium implants, for histological and histomorphometric evaluation.
6 implants (3 tests and 3 controls) will be used to evaluate and compare osseointegration, via histological and histomorphometrical analysis, in the area of the wisdom teeth ("non useful" sites that will not interfere with the rest of the study or the patient's life) - it can only be performed in patients who no longer have these teeth. The procedure will match that described for Groups A-B-C-D. In this case, implants will only remain in the mouth for 2 months, after which they will be removed for analysis. The extraction will be performed with local anesthesia. A flap will be raised to expose the implant and, using a trephine bur (1 mm wider than the implant diameter), a bone cylinder containing the implant will be extracted. The resulting bone defect and regeneration process will be similar to those following a normal molar extraction. The flap will be sutured and primary curing is expected. A new implantation will not be carried out since in this area it is totally unnecessary.




Primary Outcome Measures :
  1. Implant performance verification: implant survival rate. Change will be assessed. [ Time Frame: Day 1 (abutment connection), 3 months, 6 months, 1 year. ]
    Number of functional implants vs. number of implants inserted.

  2. Implant performance verification: osseointegration (in vivo). Change will be assessed. [ Time Frame: Day 1 (abutment connection), 3 months, 6 months, 1 year. ]
    Osseointegration quality: implant stability will be assessed via metal instrument tapping - the transmitted sound will indicate good/bad osseointegration.

  3. Implant performance verification: osseointegration (in vivo). Change will be assessed. [ Time Frame: Day 1 (abutment connection), 3 months, 6 months, 1 year. ]
    Osseointegration quantity: distance from the implant platform to the first bone contact (assessed via probing).

  4. Implant performance verification: osseointegration (in vivo). Change will be assessed. [ Time Frame: Day 1 (abutment connection), 3 months, 6 months, 1 year. ]
    Osseointegration quantity: bone to implant contact (BIC) (assessed via standard parallel periapical radiographs).

  5. Implant performance verification: osseointegration (in vivo). Change will be assessed. [ Time Frame: Day 1 (abutment connection), 3 months, 6 months, 1 year. ]
    Osseointegration quantity: bone density/quality (assessed via standard parallel periapical radiographs).

  6. Implant performance verification: osseointegration (ex vivo). [ Time Frame: 2 months after implantation. ]
    Please refer to Arms and Interventions, Experimental: Group E. For ethical reasons, this sample size is limited to six (6) implants, 3 test and 3 controls. Trephined blocks containing the explanted implants will be stored in a 5% formaldehyde solution (pH 7). They will be immersed in a 4% formaldehyde and 1% calcium solution and processed for ground sectioning following the Donath & Breuner methods. Each implant block will be individualized, embedded in methyl-methacrylate and stained with combined Harris Haematoxyline and Wheatley. The analysis will be performed using a transmitted light microscope equipped with a digital camera. Results will be inferred to clinical osseointegration data, which is the way to assess osseointegration in everyday chairside practice.

  7. G3-coated abutment performance in peri-implantitis prevention. Change will be assessed. [ Time Frame: Day 1 (abutment connection), 3 months, 6 months, 1 year. ]
    Assessment of peri-implant inflammation sign: bleeding on probing (BOP).

  8. G3-coated abutment performance in peri-implantitis prevention. Change will be assessed. [ Time Frame: Day 1 (abutment connection), 3 months, 6 months, 1 year. ]
    Assessment of gingival alteration sign: gingival clinical attachment level (CAL). Peri-implantitis is defined as bone loss around implants, so crestal bone loss will be assessed using the gold standard parallel X-Ray technique to evaluate any changes in bone to implant contact (BIC) at both mesial and distal aspects of all implants.

  9. G3-coated abutment performance in peri-implantitis prevention. Change will be assessed. [ Time Frame: Day 1 (abutment connection), 3 months, 6 months, 1 year. ]
    Assessment of crestal bone loss. Peri-implantitis is defined as bone loss around implants, so crestal bone loss will be assessed using the gold standard parallel X-Ray technique to evaluate any changes in bone to implant contact (BIC) at both mesial and distal aspects of all implants.


Secondary Outcome Measures :
  1. Prosthetic complications. Change will be assessed. [ Time Frame: Day 1 (abutment connection), 3 months, 6 months, 1 year. ]
    Assessment of parameters that may act as predisposing factors for prosthetic complications (checklist: smoker; drinking habits, etc.).



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 80 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Males/females of age 18-80.
  • Availability for the 18 months duration of the clinical trial.
  • Subject able and willing to follow study procedures and instructions.
  • Subject read, understood and signed an informed consent form.
  • Participants in need of dental implant treatment and that meet one of the following criteria:

    • Moderate to advanced periodontitis.
    • History of dental loss attributed to periodontitis.
    • Risk factors associated with periodontitis (tobacco consumption, poor oral hygiene, diabetes patients outside of the ideal range control (HbA1c <7)).
  • Good general health at time of inclusion.
  • Subjects willing to disclose information on medication.

Exclusion Criteria:

  • Female patients who report being pregnant or lactating, or who are of childbearing potential and are not using hormonal, barrier methods of birth control or abstinence.
  • Subject chronically treated (≥ two weeks) with any medication known to affect inflammation or periodontal status six months prior to enrollment or during the study.
  • Subject necessitating antibiotic for 1 month during the study.
  • Gross oral pathology.
  • Participation in any other clinical study or test panel within one month prior to entry into the study.
  • History of neoplastic disease requiring the use of chemotherapy.
  • Patients with history of renal failure or chronic renal diseases.
  • Patients affected by chronic liver diseases.
  • Patients with severe or uncontrolled metabolic bone disorders.
  • Conditions or circumstances, in the opinion of the investigator, which could represent a general contra-indication for undergoing surgery, or could prevent study completion or interfere with the analysis of the results, such as a history of non-compliance or unreliability.
  • History of local radiation therapy.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03977714


Contacts
Layout table for location contacts
Contact: Lidia M Goyos Ball, PhD +34984836852 l.goyos@nanoker.com
Contact: Ramón Torrecillas San Millán, Prof. +34984836852 r.torrecillas@nanoker.com

Locations
Layout table for location information
Spain
ICOA Noroeste SLP Recruiting
Las Rozas, Madrid, Spain, 28232
Contact: Roberto López Píriz, MD, DDs, PhD    +34916266012    lopezpiriz@gmail.com   
Sub-Investigator: María José Pérez Bastidas         
Sub-Investigator: Irene Mateo Mediavilla         
Sponsors and Collaborators
Nanoker Research S.L.
Horizon 2020 - European Commission
ICOA Noroeste SLP
National Research Council, Spain
Experior
Investigators
Layout table for investigator information
Principal Investigator: Roberto López Píriz, MD, DDS, PhD ICOA Noroeste SLP

Layout table for additonal information
Responsible Party: Nanoker Research S.L.
ClinicalTrials.gov Identifier: NCT03977714     History of Changes
Other Study ID Numbers: INPERIO
812065-INPERIO ( Other Grant/Funding Number: EUROPEAN COMMISSION - EASME )
18/497-R_P ( Other Identifier: CEIC Hospital Clínico San Carlos )
712/18/EC ( Other Identifier: AEMPS )
First Posted: June 6, 2019    Key Record Dates
Last Update Posted: June 6, 2019
Last Verified: June 2019

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Nanoker Research S.L.:
peri-implantitis
ceramic dental implant
non-invasive
periodontal disease
metal-free
Additional relevant MeSH terms:
Layout table for MeSH terms
Peri-Implantitis
Periodontal Diseases
Mouth Diseases
Stomatognathic Diseases